Polynucleotides encoding telomerase reverse transcriptase (TERT) fusion
proteins are provided, the TERT fusion proteins comprising a TERT
protein, or functional variant thereof, fused to a substantial portion of
the B subunit of heat labile enterotoxin (LTB). TERT variants useful in
TERT-LTB fusion proteins of the invention comprise mutations that
function to eliminate telomerase catalytic activity. The polynucleotides
of the present invention can elicit an immune response in a mammal,
which, in preferred embodiments, is stronger than the immune response
elicited by a wild-type TERT. TERT expression is commonly associated with
the development of human carcinomas. The present invention provides
compositions and methods to elicit or enhance immunity to the protein
product expressed by the TERT tumor-associated antigen, wherein aberrant
TERT expression is associated with a carcinoma or its development. This
invention specifically provides adenoviral vector and plasmid constructs
carrying polynucleotides encoding TERT fusion proteins and TERT variants
and discloses their use in vaccines and pharmaceutical compositions for
preventing and treating cancer.